Funder
European Medicines Agency
Università degli Studi di Verona
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study [published correction appears in Lancet. 2020 Sep 12;396(10253):758]. Lancet. 2020;395(10241):1907–18. https://doi.org/10.1016/S0140-6736(20)31187-9.
2. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91. https://doi.org/10.1158/2159-8290.CD-20-0422.
3. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385–401. https://doi.org/10.1038/s41571-022-00610-8.
4. Centre for Disease Control and Prevention (CDC). COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. Accessed 20 Sept 2023.
5. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. https://www.ema.europa.eu/en/news/comirnaty-and-spikevax-ema-recommendations-extra-doses-and-boosters. Accessed Sept 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献